,
,
,
Predicting factors for arrhythmia during follow-up ,
,
,
,
,
Echocardiographic and Doppler assessment of hypertrophic cardiomyopathy, J Am Soc Echocardiogr Off Publ Am Soc Echocardiogr, vol.1, pp.31-47, 1988. ,
Patterns and significance of distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy. A wide angle, two dimensional echocardiographic study of 125 patients, Am J Cardiol, vol.48, pp.418-446, 1981. ,
Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction, Circulation, vol.114, pp.2232-2241, 2006. ,
Hypertrophic cardiomyopathy. The importance of the site and the extent of hypertrophy. A review, Prog Cardiovasc Dis, vol.28, pp.1-83, 1985. ,
Recommendations for transoesophageal echocardiography: update 2010, Eur J Echocardiogr J Work Group Echocardiogr Eur Soc Cardiol, vol.15, pp.557-76, 2010. ,
Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy, JACC Cardiovasc Imaging, vol.5, pp.370-377, 2012. ,
Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy, Circulation, vol.107, pp.2227-2259, 2003. ,
Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases, Eur Heart J, vol.31, pp.2715-2741, 2010. ,
Effect of sotalol on arrhythmias and exercise tolerance in patients with hypertrophic cardiomyopathy, Cardiology, vol.82, pp.335-377, 1993. ,
Muscular subaortic stenosis. Prevention of outflow obstruction with propranolol, Circulation, vol.38, pp.846-58, 1968. ,
Use of calcium-channel blocking drugs in hypertrophic cardiomyopathy, Am J Cardiol, vol.55, pp.185-195, 1985. ,
Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. I. Hemodynamic effects, Circulation, vol.60, pp.1201-1208, 1979. ,
Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy, J Am Coll Cardiol, vol.45, pp.1251-1259, 2005. ,
Hypertrophic cardiomyopathy and sudden death, N Engl J Med, vol.318, pp.1255-1262, 1988. ,
Hypertrophic cardiomyopathy: a systematic review, JAMA, vol.287, pp.1308-1328, 2002. ,
Cardiac arrest during long-distance running races, N Engl J Med, vol.366, pp.130-170, 2012. ,
Sudden death in young athletes, N Engl J Med, vol.349, pp.1064-75, 2003. ,
Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy, N Engl J Med, vol.342, pp.365-73, 2000. ,
Long-term followup of implantable cardioverter defibrillator therapy for hypertrophic cardiomyopathy, Am J Cardiol, vol.93, pp.1192-1196, 2004. ,
Outcome and complications after implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy: systematic review and meta-analysis, Circ Heart Fail, vol.5, pp.552-561, 2012. ,
Risks and challenges of implantable cardioverter-defibrillators in young adults, Prog Cardiovasc Dis, vol.51, pp.237-63, 2008. ,
,
, American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines, J Am Coll Cardiol, vol.42, pp.1687-713, 2003.
ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, J Am Coll Cardiol, vol.58, pp.2703-2741, 2011. ,
Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients, J Am Coll Cardiol, vol.42, pp.873-882, 2003. ,
Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy, Circulation, vol.96, pp.2987-91, 1997. ,
Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy, N Engl J Med, vol.342, pp.1778-85, 2000. ,
Syncope and risk of sudden death in hypertrophic cardiomyopathy, Circulation, vol.119, pp.1703-1713, 2009. ,
A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD), Eur Heart J, vol.35, pp.2010-2030, 2014. ,
ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC), Eur Heart J, vol.35, pp.2733-79, 2014. ,
Hypertrophic Cardiomyopathy and Implantable Defibrillators in Sweden: Inappropriate Shocks and Complications Requiring Surgery, J Cardiovasc Electrophysiol, vol.26, pp.1088-94, 2015. ,
The longterm survival and the risks and benefits of implantable cardioverter defibrillators in patients with hypertrophic cardiomyopathy, Heart Br Card Soc, vol.98, pp.116-141, 2012. ,
Implantable cardioverterdefibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy, JAMA, vol.298, pp.405-417, 2007. ,
Reduction in inappropriate therapy and mortality through ICD programming, N Engl J Med, vol.367, pp.2275-83, 2012. ,
Influence of beta-blocker therapy on antitachycardia pacing effectiveness for monomorphic ventricular tachycardias occurring in implantable cardioverter-defibrillator patients: a dosedependent effect. Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol, vol.12, pp.1231-1239, 2010. ,
Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy: patient outcomes, rate of appropriate and inappropriate interventions, and complications, Am Heart J, vol.166, pp.496-502, 2013. ,
Defibrillation threshold testing in patients with hypertrophic cardiomyopathy, Pacing Clin Electrophysiol PACE, vol.33, pp.1342-1348, 2010. ,
Cardioverter-defibrillator implantation in high-risk patients with hypertrophic cardiomyopathy, Heart Rhythm Off J Heart Rhythm Soc, vol.2, pp.814-823, 2005. ,
Cardioverter defibrillator implantation without induction of ventricular fibrillation: a single-blind, non-inferiority, randomised controlled trial (SIMPLE), Lancet Lond Engl, vol.385, pp.785-91, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01132536
Does defibrillation testing influence outcomes after CRT-D implantation? A cause-of-death analysis from the DAI-PP study, Int J Cardiol, vol.221, pp.951-957, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01414470
Role of defibrillation threshold testing during implantable cardioverter-defibrillator placement: data from the Israeli ICD Registry, Heart Rhythm Off J Heart Rhythm Soc, vol.11, pp.814-835, 2014. ,
Systematic Review of Defibrillation Threshold Testing at De Novo Implantation, Circ Arrhythm Electrophysiol, vol.9, p.3357, 2016. ,
Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases, Eur Heart J, vol.31, pp.2715-2741, 2010. ,
Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy, Circulation, vol.112, pp.855-61, 2005. ,
Evidence that pharmacological strategies lack efficacy for the prevention of sudden death in hypertrophic cardiomyopathy, Heart Br Card Soc, vol.93, pp.708-718, 2007. ,
Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia, Br Heart J, vol.53, pp.412-418, 1985. ,
Muscular subaortic stenosis. Prevention of outflow obstruction with propranolol, Circulation, vol.38, pp.846-58, 1968. ,
Effect of sotalol on arrhythmias and exercise tolerance in patients with hypertrophic cardiomyopathy, Cardiology, vol.82, pp.335-377, 1993. ,
Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review, Heart Br Card Soc, vol.100, pp.465-72, 2014. ,
,
, Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy, JAMA, vol.298, issue.4, pp.405-417, 2007.
,
Outcome and complications after implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy: systematic review and meta-analysis. Circ Heart Fail, vol.5, pp.552-561, 2012. ,
Hypertrophic Cardiomyopathy and Implantable Defibrillators in Sweden: Inappropriate Shocks and Complications Requiring Surgery, J Cardiovasc Electrophysiol, vol.26, issue.10, pp.1088-94, 2015. ,
The long-term survival and the risks and benefits of implantable cardioverter defibrillators in patients with hypertrophic cardiomyopathy, 2012. ,
Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy: patient outcomes, rate of appropriate and inappropriate interventions, and complications, Am Heart J, vol.166, issue.3, pp.496-502, 2013. ,
,
, Cardioverter defibrillator implantation without induction of ventricular fibrillation: a single-blind, non-inferiority, randomised controlled trial (SIMPLE), vol.385, pp.785-91, 2015.
Does defibrillation testing influence outcomes after CRT-D implantation? A cause-of-death analysis from the DAI-PP study, Int J Cardiol, vol.221, pp.951-957, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01414470
Systematic Review of Defibrillation Threshold Testing at De Novo Implantation, Circ Arrhythm Electrophysiol, vol.9, issue.4, p.3357, 2016. ,
Role of defibrillation threshold testing during implantable cardioverter-defibrillator placement: data from the Israeli ICD Registry, Heart Rhythm Off J Heart Rhythm Soc, vol.11, issue.5, pp.814-835, 2014. ,
Cardioverter-defibrillator implantation in high-risk patients with hypertrophic cardiomyopathy, Heart Rhythm Off J Heart Rhythm Soc, vol.2, issue.8, pp.814-823, 2005. ,
Defibrillation threshold testing in patients with hypertrophic cardiomyopathy, Pacing Clin Electrophysiol PACE, vol.33, issue.11, pp.1342-1348, 2010. ,
American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines, J Am Coll Cardiol, vol.42, issue.9, pp.1687-713, 2003. ,
, , 2011.
, ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, J Am Coll Cardiol, vol.58, issue.25, pp.2703-2741, 2011.
A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD), Eur Heart J, vol.35, issue.30, pp.2010-2030, 2014. ,
ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC), Eur Heart J, vol.35, issue.39, pp.2733-79, 2014. ,
Validation of the 2014 European Society of Cardiology Sudden Cardiac Death Risk Prediction Model in Hypertrophic Cardiomyopathy in a Reference Center in South America, Am J Cardiol, vol.118, issue.1, pp.121-127, 2016. ,
,
Validation of the 2014 European Society of Cardiology guidelines risk prediction model for the primary prevention of sudden cardiac death in hypertrophic cardiomyopathy, Circ Arrhythm Electrophysiol, vol.8, issue.4, pp.829-864, 2015. ,
Independent Assessment of the European Society of Cardiology Sudden Death Risk Model for Hypertrophic Cardiomyopathy, Am J Cardiol, vol.116, issue.5, pp.757-64, 2015. ,
Reduction in inappropriate therapy and mortality through ICD programming, N Engl J Med, vol.367, issue.24, pp.2275-83, 2012. ,
Effect of long-detection interval vs standard-detection interval for implantable cardioverter-defibrillators on antitachycardia pacing and shock delivery: the ADVANCE III randomized clinical trial, JAMA, vol.309, issue.18, pp.1903-1914, 2013. ,
Dualchamber implantable cardioverter-defibrillator selection is associated with increased complication rates and mortality among patients enrolled in the NCDR implantable cardioverter-defibrillator registry, J Am Coll Cardiol, vol.58, issue.10, pp.1007-1020, 2011. ,
An entirely subcutaneous implantable cardioverter-defibrillator, N Engl J Med, vol.363, issue.1, pp.36-44, 2010. ,
Worldwide experience with a totally subcutaneous implantable defibrillator: early results from the EFFORTLESS S-ICD Registry, Eur Heart J, vol.35, issue.25, pp.1657-65, 2014. ,
Combined leadless pacemaker and subcutaneous implantable defibrillator therapy: feasibility, safety, and performance. Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol, vol.18, pp.1740-1747, 2016. ,